Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer

NCT02228369 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

108

Enrollment

INDUSTRY

Sponsor class

Conditions

EGFR Mutation Positive Advanced Non Small Cell Lung Cancer

Interventions

DRUG: AZD3759
DRUG: AZD9291

Sponsor

AstraZeneca